Human tumor sequencing studies have identified multiple alterations in SWI/SNF across a range of malignancies10 and activating EZH2 mutations in lymphoma (and over-expression in other tumors)7, 11, 12, 13, 14, and in some these have been correlated with worse clinical outcomes15. This evidence concerns the gene EZH2 and lymphoma.